1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedarplus.ca under the Company’s profile.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Resverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & Analysis
December 14, 2017
Nature’s Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
December 12, 2017
Resverlogix Announces Voting Results From The 2017 Annual Meeting Of Shareholders
December 12, 2017
Resverlogix Repays $68.8 Million Loan
December 6, 2017
Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
December 4, 2017
Resverlogix Announces Participation in Upcoming Conferences
November 2, 2017
Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
November 1, 2017
Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc.
October 24, 2017
Resverlogix Announces $87 Million Private Placement with Shenzhen Hepalink
October 13, 2017
Resverlogix Announces Annual and Special Meeting of Shareholders
October 2, 2017
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
September 13, 2017
Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
September 5, 2017
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
August 29, 2017
Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
August 28, 2017
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
July 25, 2017
Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
July 25, 2017
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
July 10, 2017
Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
June 28, 2017
Resverlogix Comments on TSX Trader Notes
June 21, 2017
Resverlogix Closes $10 Million of Equity Subscriptions
June 20, 2017
Resverlogix to Raise Up To $10 Million
June 9, 2017
Resverlogix Announces Overnight Marketed Equity Offering
June 8, 2017
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
June 5, 2017
Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
May 31, 2017
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
May 30, 2017
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
May 23, 2017
Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
May 15, 2017
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities
March 17, 2017
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
March 15, 2017
Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
February 23, 2017
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
February 13, 2017
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
January 23, 2017
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA
January 5, 2017